Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis

The objective of this study was to compare ticarcillin/clavulanate given at 3.1 g every 6 hours with imipenem/cilistatin given at 500 mg every 6 hours for the treatment of infections associated with gangrenous or perforated a ppendicitis. One hundred thirty-seven patients were found to have gangrenou s or perforated appendicitis and received the study medication for 3 to 5 d ays in a double-blinded, randomized manner. Clinical success was similar fo r the two treatment groups, 96.9 and 95.9 per cent in the ticarcillin/clavu lanate and imipenem/cilistatin groups, respectively (P = 0.99; 95% confiden ce interval for the difference was -5.6% to 7.6%). Bacteriologic success at the end of therapy was similar in the two groups, 100 and 98.4 per cent in the ticarcillin/clavulanate and imipenem/ cilistatin groups, respectively (P = 0.99; 95% confidence interval for the difference was -1.8% to 4.7%). T he occurrence of adverse events related to treatment was similar for the tw o groups (P = 0.31) and led to study withdrawal for four patients (one with ticarcillin/clavulanate and three with imipenem/cilistatin). Ticarcillin/c lavulanate given at 3.1 g every 6 hours is as effective and as safe as imip enem/cilistatin given at 500 mg every 6 hours for treatment of gangrenous o r perforated appendicitis.